Disease · MONDO_0005340
alopecia areata
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. alopecia areata. Diseases, record MONDO_0005340. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005340
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Approval, for 3 of its 74 drugs, from EMA Human Drugs, FDA, PMDA and TTD
- Open Targets
Drugs74
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RITLECITINIB | CHEMBL4085457 | Small molecule | Approval | EMA Human Drugs and TTD | 14 | 12 | 12 | Drugs and targets |
| RITLECITINIB TOSYLATE | CHEMBL5314649 | Small molecule | Approval | FDA and PMDA | 3 | 1 | 1 | Drugs and targets |
| DEURUXOLITINIB PHOSPHATE | CHEMBL4594382 | Small molecule | Approval | FDA | 2 | 0 | 0 | Drugs and targets |
| DEURUXOLITINIB | CHEMBL4594381 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 9 | 9 | Drugs and targets |
| BARICITINIB | CHEMBL2105759 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| TOFACITINIB | CHEMBL221959 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| UPADACITINIB | CHEMBL3622821 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ALDESLEUKIN | CHEMBL1201438 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CLOBETASOL PROPIONATE | CHEMBL1159650 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| HYDROCORTISONE | CHEMBL389621 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
1 to 10 of 74
See all 74 drugsTargets117
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 12 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| JAK1 | Janus Kinase (JAK) | 10 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor | Approval | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 8 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor | Approval | https://conductscience.org/library/genes/3717 | Drugs and targets |
| JAK3 | Janus Kinase (JAK) | 8 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor | Approval | https://conductscience.org/library/genes/3718 | Drugs and targets |
| TYK2 | Janus Kinase (JAK) | 8 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator | Approval | https://conductscience.org/library/genes/7297 | Drugs and targets |
| PDE4A | 3',5'-cyclic phosphodiesterase | 3 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor | Phase 2 | https://conductscience.org/library/genes/5141 | Drugs and targets |
| PDE4B | 3',5'-cyclic phosphodiesterase | 3 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor | Phase 2 | https://conductscience.org/library/genes/5142 | Drugs and targets |
| PDE4C | 3',5'-cyclic phosphodiesterase | 3 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor | Phase 2 | https://conductscience.org/library/genes/5143 | Drugs and targets |
| PDE4D | 3',5'-cyclic phosphodiesterase | 3 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor | Phase 2 | https://conductscience.org/library/genes/5144 | Drugs and targets |
| SNAP25 | Synaptosomal-associated protein 25 | 3 | Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | Unknown | https://conductscience.org/library/genes/6616 | Drugs and targets |
1 to 10 of 117
See all 117 targetsTrials103
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04006457 | Long-Term PF-06651600 for the Treatment of Alopecia Areata | Phase 3 | 1,057 | 2025-08-14 | Alopecia Areata | RITLECITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03570749 | A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata | Phase 2/3 | 784 | 2025-10-01 | Alopecia Areata | BARICITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03732807 | PF-06651600 for the Treatment of Alopecia Areata | Phase 2/3 | 718 | 2022-02-24 | Alopecia Areata | RITLECITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04518995 | Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) | Phase 3 | 706 | 2023-05-03 | Alopecia Areata | DEURUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03899259 | A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata | Phase 3 | 606 | 2024-05-14 | Alopecia Areata | BARICITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04797650 | Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) | Phase 3 | 517 | 2023-07-03 | Alopecia Areata | DEURUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT05041803 | European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | Phase 3 | 407 | 2025-11-21 | Alopecia Areata | DEURUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04784533 | A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata | Phase 2 | 317 | 2024-10-09 | Alopecia Areata | DEURUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03137381 | Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata | Phase 2 | 149 | 2022-07-19 | Alopecia Areata | DEURUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02974868 | Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata | Phase 2 | 142 | 2020-05-26 | Alopecia Areata | BREPOCITINIB, RITLECITINIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 103
See all 103 trialsComparisons in its trials36
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) vs Main Study: Ritlecitinib 50 mg QD (Roll-over Participants): Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until Follow-up Visit | 401 of 447 | 515 of 603 | 1,050 | NCT04006457 | Trial comparisons |
Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) vs Main Study: Ritlecitinib 50 mg QD (Roll-over Participants): Main Study: Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values Until Follow-up Visit | 390 of 444 | 490 of 602 | 1,046 | NCT04006457 | Trial comparisons |
| CTP-543 8 mg BID vs CTP-543 12 mg BID: deaths from any cause | 0 of 367 | 0 of 273 | 640 | NCT05041803 | Trial comparisons |
| CTP-543 8 mg BID vs CTP-543 12 mg BID: Number of Participants With Adverse Events as a Measure of Safety | 308 of 367 | 224 of 273 | 640 | NCT05041803 | Trial comparisons |
| CTP-543 8 mg BID vs CTP-543 12 mg BID: serious adverse events | 16 of 367 | 5 of 273 | 640 | NCT05041803 | Trial comparisons |
| Ruxolitinib Cream vs Placebo Cream: deaths from any cause | 0 of 83 | 0 of 38 | 121 | NCT02553330 | Trial comparisons |
| Ruxolitinib Cream vs Placebo Cream: serious adverse events | 4 of 83 | 0 of 38 | 121 | NCT02553330 | Trial comparisons |
| Part B: Ruxolitinib Cream vs Part B : Placebo Cream: Part B : Percentage of Participants Achieving a SALT50 Response in Terminal Hair (Pigmented and Nonpigmented) | 5 of 39 | 5 of 39 | 78 | NCT02553330 | Trial comparisons |
Part B : Ruxolitinib Cream vs Part B : Placebo Cream: Part B : Percentage of Subjects Whose AA Lesions Treated Since Baseline Achieved a Physician's Global Assessment of Regrowth (PGARG) Score of at Least 3 | 2 of 33 | 5 of 33 | 66 | NCT02553330 | Trial comparisons |
| CTP-543 12 mg BID vs CTP-543 24 mg QD: Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE) | 28 of 34 | 24 of 32 | 66 | NCT03941548 | Trial comparisons |
1 to 10 of 36
See all 36 comparisons in its trialsPapers from its trials80
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005340
GET https://conductscience.org/api/diseases/v1/MONDO_0005340/drugs?page=2